Thermo Fisher Scientific (TMO) : At Bancorp reduced its stake in Thermo Fisher Scientific by 1.18% during the most recent quarter end. The investment management company now holds a total of 16,671 shares of Thermo Fisher Scientific which is valued at $2,534,492 after selling 199 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Thermo Fisher Scientific makes up approximately 0.35% of At Bancorp’s portfolio.
Other Hedge Funds, Including , Cohen Capital Management boosted its stake in TMO in the latest quarter, The investment management firm added 650 additional shares and now holds a total of 79,320 shares of Thermo Fisher Scientific which is valued at $12,059,020. Thermo Fisher Scientific makes up approx 3.62% of Cohen Capital Management’s portfolio.Gofen Glossberg Il reduced its stake in TMO by selling 4,567 shares or 1.24% in the most recent quarter. The Hedge Fund company now holds 364,806 shares of TMO which is valued at $58,044,283. Thermo Fisher Scientific makes up approx 2.42% of Gofen Glossberg Il’s portfolio.Oregon Public Employees Retirement Fund boosted its stake in TMO in the latest quarter, The investment management firm added 16,611 additional shares and now holds a total of 92,730 shares of Thermo Fisher Scientific which is valued at $14,754,270. Thermo Fisher Scientific makes up approx 0.32% of Oregon Public Employees Retirement Fund’s portfolio. Fisher Asset Management added TMO to its portfolio by purchasing 1,482 company shares during the most recent quarter which is valued at $235,801.Lenox Wealth Advisors reduced its stake in TMO by selling 6 shares or 1.54% in the most recent quarter. The Hedge Fund company now holds 384 shares of TMO which is valued at $60,780. Thermo Fisher Scientific makes up approx 0.02% of Lenox Wealth Advisors’s portfolio.
Thermo Fisher Scientific closed down -4.21 points or -2.65% at $154.9 with 26,97,528 shares getting traded on Tuesday. Post opening the session at $156, the shares hit an intraday low of $153.79 and an intraday high of $156.585 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Thermo Fisher Scientific reported $2.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $2.01. The company had revenue of $4535.20 million for the quarter, compared to analysts expectations of $4493.28 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.84 EPS.
Many Wall Street Analysts have commented on Thermo Fisher Scientific. JP Morgan Resumed Thermo Fisher Scientific on Sep 22, 2016 to “Overweight”, Price Target of the shares are set at $180.Thermo Fisher Scientific was Downgraded by Cleveland Research to ” Neutral” on Sep 9, 2016.
Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.